In a phase I tolerability study, the CRM1 inhibitor selinexor was tolerable at doses as high as 55 mg/m2 in combination with fludarabine and cytarabine in pediatric patients with relapsed or refractory leukemia [41]. Here, XPO1 is linked to leukemia.